A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing–remitting multiple sclerosis
- 28 May 2023
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 270 (9) , 4403-4414
Abstract
Background Multiple sclerosis (MS) is associated with regulatory T cells (Tregs) insufficiency while low-dose interleukin-2 (IL2LD) activates Tregs and reduces disease activity in autoimmune diseases. Methods We aimed at addressing whether IL2LD improved Tregs from MS patients. MS-IL2 was a single-center double-blind phase-2 study. Thirty patients (mean [SD] age 36.8 years [8.3], 16 female) with relapsing–remitting MS with new MRI lesions within 6 months before inclusion were randomly assigned in a 1:1 ratio to placebo or IL-2 at 1 million IU, daily for 5 days and then fortnightly for 6 months. The primary endpoint was change in Tregs at day-5. Results Unlike previous trials of IL2LD in more than 20 different autoimmune diseases, Tregs were not expanded at day-5 in IL2LD group, but only at day-15 (median [IQR] fold change from baseline: 1.26 [1.21–1.33] in IL2LD group; 1.01 [0.95–1.05] in placebo group, p < 0.001). At day-5, however, Tregs had acquired an activated phenotype (fold change of CD25 expression in Tregs: 2.17 [1.70–3.55] in IL2LD versus 0.97 [0.86–1.28] in placebo group, p < 0.0001). Regulator/effector T cells ratio remained elevated throughout treatment period in the IL2LD group (p < 0.001). Number of new active brain lesions and of relapses tended to be reduced in IL2LD treated patients, but the difference did not reach significance in this trial not powered to detect clinical efficacy. Conclusion The effect of IL2LD on Tregs in MS patients was modest and delayed, compared to other auto-immune diseases. This, together with findings that Tregs improve remyelination in MS models and recent reports of IL2LD efficacy in amyotrophic lateral sclerosis, warrants larger studies of IL2LD in MS, notably with increased dosages and/or modified modalities of administration. Trial registration information ClinicalTrials.gov: NCT02424396; EU Clinical trials Register: 2014-000088-42.Keywords
Funding Information
- Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques
- ANR (ANR-16-RHUS-0001)
This publication has 41 references indexed in Scilit:
- Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trialThe Lancet Diabetes & Endocrinology, 2013
- Interleukin-2 and Regulatory T Cells in Graft-versus-Host DiseaseNew England Journal of Medicine, 2011
- Identification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune diseaseNature Medicine, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Regulatory T cells fail to suppress CD4+ T‐bet+ T cells in relapsing multiple sclerosis patientsImmunology, 2009
- FOXP3 modifies the phenotypic and functional properties of regulatory T cellsNature Reviews Immunology, 2007
- Secondary progressive in contrast to relapsing‐remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T‐cell function and FOXP3 expressionJournal of Neuroscience Research, 2006
- Decreased FOXP3 levels in multiple sclerosis patientsJournal of Neuroscience Research, 2005
- Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple SclerosisJournal of Experimental Medicine, 2004
- Sample Size Determination for Some Common Nonparametric TestsJournal of the American Statistical Association, 1987